Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state

European Journal of Heart Failure

Volumn 9, Issue 1, 2007, Pages 68-74

  Schou, Morten ^a   Gustafsson, Finn ^b   Nielsen, Per H ^a   Madsen, Lene H ^a   Kjaer, Andreas ^b,c   Hildebrandt, Per R ^a  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

BNP; Chronic heart failure; NT proBNP; Reference change value; Unexplained variation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HEART FAILURE; HOMEOSTASIS; HUMAN; LABORATORY TEST; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SAMPLE SIZE; STEADY STATE; VARIANCE;

AGED; AGED, 80 AND OVER; ALGORITHMS; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NATRIURETIC PEPTIDE, BRAIN; PATIENT SELECTION; PEPTIDE FRAGMENTS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 33846079081     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2006.05.001     Document Type: Article

References (42)

1. Doust J., Pietrzak F., Dobson A., and Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330 (2005) 625-634
2. Maisel A.S., Krishnashwamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. NEJM 347 (2002) 161-167
3. Januzzi Jr. J.L., Camarco C.G., Anwarrudin S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 (2005) 948-954
4. McDonagh T.A., Robb S.D., Murdoch D.R., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 351 (1998) 9-13
5. Gustafsson F., Steensgaard-Hansen F., Badskjaer J., Poulsen A.H., Corell P., and Hildebrandt P.R. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail 11 (2005) S15-S20
6. Bruins S., Fokkema M.R., Romer J.W.P., et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50 (2004) 2052-2058
7. Wu A.H., Smith A., Wieczorek S., et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92 (2003) 628-631
8. Iglesias N., Petersen P.H., and Ricos C. Reference change values and power functions. Clin Chem Lab Med 42 (2004) 415-422
9. Murdoch D.R., McDonagh T.A., Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138 (1999) 1126-1132
10. Anand I., Fisher L.D., Chiang Y.T., Latini R., Masson S., and Maggioni A.P. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
11. Goetze J.P., Christoffersen C., Perko M., et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 17 (2003) 1105-1107
12. Tsucida T., and Tanabe K. Influence of paroxysmal atrial fibrillation attack on brain natriuretic peptide secretion. J Cardiol 44 (2004) 1-11
13. Hoffmann U., Brueckmann M., Bertsch T., Wiessner M., Liebetrau C., and Lang S. Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. Clin Lab 51 (2005) 373-379
14. Hartmann F., Packer M., Coats A.J., Fowler M.B., Krum H., and Mohacsi P. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 6 (2004) 343-350
15. Tsutamoto T., Wada A., Maeda K., Mabuchi M., Hayashi M., and Tsutsui T. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 37 (2001) 1228-1233
16. Tsutamoto T., Wada A., Maeda K., Hisanage T., Fukai D., and Maeda Y. Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. Am Heart J 134 (1997) 910-916
17. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 (2002) 1623-1629
18. Harris E.K. Effects of intra- and inter-individual variation on the appropriate use of normal ranges. Clin Chem 20 (1974) 1535-1542
19. Petersen P.H., Sandberg S., Fraser C.G., and Goldschmidt H. Influence of index of individuality on false positives in repeated sampling from healthy individuals. Clin Chem Lab Med 39 (2001) 160-165
20. Iglesias N., Petersen P.H., and Ricos C. Power function of the reference change value in relation to cut-off points, reference intervals and index of individuality. Clin Chem Lab Med 43 (2005) 441-448
21. Fraser C.G., and Harris E.K. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 27 (1989) 409-437
22. Galatius S., Gustafsson F., Nielsen P.H., Atar D., and Hildebrandt P.R. An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area. Am Heart J 144 (2002) E2
23. Wu A.H., Packer M., Smith A., et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 50 (2004) 867-873
24. Sokoll L.J., Baum H., Collinson P.O., et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med 42 (2004) 965-972
25. Junge W., Wilke B., Halabi A., and Klein G. Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method. Clin Chim Acta 344 (2004) 137-148
26. Kroll M.H. Biological variation of glucose and insulin includes a deterministic chaotic component. Biosystems 50 (1999) 189-201
27. Bentzen H., Pedersen R.S., Pedersen H.B., and Pedersen E.B. Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure. Clin Sci 104 (2003) 303-312
28. Woo M.A., Stevenson W.G., Moser D.K., Trelease D.K., and Harper R.M. Patterns of beat-to-beat heart rate variability and its association with increased mortality in advanced heart failure. Am Heart J 123 (1992) 704-710
29. Dirksen A., Holstein-Rathlou N.H., Madsen F., et al. Long-range correlations of serial FEV1 measurements in emphysematous patients and normal subjects. J Appl Physiol 85 (1998) 259-265
30. McCarter R.J., Hempe J.M., Gomez R., and Chalew S.A. Biological variation in HbA1C predicts risk of retinopathy and nephropathy in type diabetes. Diabetes Care 27 (2004) 1259-1264
31. Harris E.K., and Yasaka T. On the calculation of a "reference change" for comparing two consecutive measurements. Clin Chem 29 (1983) 25-30
32. Fraser C.G. Optimal analytical performance for point of care testing. Clin Chem Acta 307 (2001) 37-43
33. Lang C.C., Coutie W.J., Khong T.K., Choy A.M., and Struthers A.D. Dietary sodium loading increases plasma brain natriuretic peptide levels in man. J Hypertens 9 (1991) 779-782
34. Goldberger A.L., Rigney D.R., and West B.J. Chaos and fractals in human physiology. Sci Am 262 (1990) 42-49
35. Lainchbury JG, Troughton RW, Frampton CM, Yandle TG, Hamid A, Nicholls MG et al. NT-proBNP guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail (in press).
36. Yudkin J.S., Forrst R.D., Jackson C.A., Ryle A.J., Davie S., and Gould B.J. Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia 33 (1990) 208-215
37. Kjaer A., Hildebrandt P., Appel J., and Petersen C.L. Basal and exercise-induced neuroendocrine activation in patients with heart failure and in normal subjects. Eur J Heart Fail 6 (2004) 29-39
38. Ricos C., Cava F., Garcia-Lario J.V., et al. The reference change value: a proposal to interpret laboratory reports in serial testing based on biological variation. Scand J Clin Lab Invest 64 (2004) 175-184
39. Pemberton C.J., Johnson M.L., Yandle T.G., and Espiner E.A. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 36 (2000) 355-359
40. Corboy J.C., Walker R.J., Simmonds M.B., Wilkens G.T., Richards A.M., and Espiner E.A. Plasma natriuretic peptides and cardiac volume during acute changes in intravascular volume in haemodialysis patients. Clin Sci (Lond) 87 (1994) 679-684
41. Kalra P.R., Anagnostopoulos C., Bolger A.P., Coats A.J.S., and Anker S.D. The regulation and measurement of plasma volume in heart failure. JACC 39 (2002) 1901-1908
42. Cockkroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41